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| INTRODUCTION
Infection with hepatitis C virus (HCV) is associated with substantial morbidity and mortality, and affects more than 185 million people worldwide.
1,2 HCV genotype 4 accounts for more than 8% of total HCV cases (more than 90% of HCV infections in Egypt alone), 1 and its prevalence is characterized by wide regional variations, with the highest prevalence reported for the Middle East and sub-Saharan Africa. 1 An increase in distribution of HCV genotype 4 infections has been noted globally, because of effects of migration, with several
European studies reporting 9% to 14% of HCV infections 1, 3 attributable to genotype 4. HCV genotype 4 demonstrates substantial genetic variability, with 17 confirmed subtypes. 4, 5 In Egypt, genotype 4a is the predominant subtype reported, 6, 7 whereas Saudi Arabia and parts of Europe have high rates of subtypes 4, 5 4a, 4c, and 4d. treatment-naive (n = 42) and treatment-experienced (n = 49) patients with HCV genotype 4 infection without cirrhosis. 10, 11 Although there are recommended regimens for patients with HCV genotype 4 infection with compensated cirrhosis, these patients are often underrepresented in clinical trials. [12] [13] [14] [15] [16] [17] More extensive efficacy and safety data are needed in this patient population, particularly to address the unresolved issue of appropriate treatment duration in these patients. The phase 3 AGATE-I trial was the first large, prospective clinical trial to study the efficacy and safety of an investigational agent in HCV genotype 4 patients with compensated cirrhosis across a set of three treatment durations. 18 Part I of the trial, previously 
| Outcomes
The primary efficacy end point for Part II was the proportion of patients who achieved SVR12 (HCV RNA less than lower limit of quantification at posttreatment week 12) in Arm C.
The secondary outcomes for Part II were to assess the propor- 
| Statistical analysis
The study was designed to test the hypothesis that percentages of treatment-naive and interferon-experienced HCV genotype 4-infected patients with compensated cirrhosis treated with ombitasvir/paritaprevir/ritonavir coadministered with ribavirin for 12, 16, and 24 weeks achieving SVR12 were superior to the historical rate of 67% (appendix p9). Full details of all statistical analyses carried out are available in the appendix (p9).
| RESULTS
In Part II of the AGATE-I study, 64 patients were enrolled between June 10, 2015, and November 19, 2015: 61 patients to Arm C and 3 patients to Arm D. All patients were assigned to receive 24 weeks of treatment. All patients received at least one dose of study drug.
Arm C included 30 (49%) treatment-experienced patients, of whom 13 (21%) were null responders, 7 (11%) were partial responders, and 10 (16%) were relapsers to prior treatment. All three patients in Arm D had virologic relapse after prior treatment with sofosbuvir plus ribavirin with or without pegylated interferon.
Sequence analysis identified 33 (52%) of 64 patients in Part II infected with subtype 4a (one with a mixed infection with subtype 1a), 14 (22%) with 4d, and 17 (27%) with other genotype 4 subtypes.
Full patient demographics and baseline disease characteristics are summarized in Table 1 .
SVR12 was achieved in 57 of 61 patients (93.4%; 97.5% confidence interval [CI], 82.6-97.7) in Arm C and all three patients in Arm D (100%; Figure 1 ). In Arm C, patients not achieving SVR12
were two patients with missing SVR12 data and two patients with premature discontinuation of treatment: one patient due to an adverse event of acute liver toxicity and one due to unknown Child-Pugh scores are those reported at baseline. None of these patients had any clinical decompensation episodes throughout the study.
d Based on observations from 59 patients from the Arm C and 3 patients from Arm D.
reasons. Superiority to historical rates achieved with pegylated interferon plus ribavirin was shown in Arm C because the lower bound of the 97.5% CI for SVR12 was higher than the predefined threshold (67%).
Comparison of SVR12 by HCV genotype 4 subtypes revealed that the percentages of patients achieving SVR12 for all subtypes were consistent with those of the overall intention-to-treat population, with no clinically meaningful differences between subgroups (Figure 2 ).
A sensitivity analysis excluding patients who did not achieve SVR12 for reasons other than virologic failure (eg, early discontinuation or missing SVR12 data) showed SVR12 was achieved in 57 of 57 patients (100%; 95% CI, 93.7-100) in Arm C and in all three patients in Arm D (100%; Figure 1 ).
Comparison of SVR12 rates from the 24-week treatment Arm C with Arm B using the stratum-adjusted Mantel-Haenszel method showed that no significant difference was observed in SVR12 between Figure S1 , appendix p11). Postbaseline laboratory abnormalities (regardless of baseline level)
Small improvements in
for patients in Arm C are presented in Table 2 . Grade 2 hemoglobin reductions (<10 g/dL) occurred in 7 (11%) of 61 patients, and no patient experienced a grade 3 or 4 reduction in hemoglobin (<8 g/dL; Table 2 ). In total, three patients experienced a grade 3 (>5 × ULN) elevation in ALT levels ( Table 2) . One patient had an isolated incident of ALT elevations at posttreatment week 1 (223 U/L). Two patients had prolonged elevations: The first patient (also described above) experienced acute liver toxicity with ALT elevations 166 to 219 U/L from day 15 to day 17, and the second patient experienced ALT elevations 248 to 383 U/L from weeks 2 to 6, which resulted in the patient discontinuing the study drug. ALT elevations were resolved by end of treatment in the second patient and were not associated with FIGURE 2 Efficacy of ombitasvir, paritaprevir, and ritonavir plus ribavirin in patients with hepatitis C virus genotype 4 infection and compensated cirrhosis by subtype.
*
One patient was lost to follow-up and one prematurely discontinued study drug; † patient prematurely discontinued study drug; ‡ one patient was lost to follow-up In the latter case, concomitant increases in ALT and total bilirubin levels to grade 3 were reported; however, levels returned to normal after study drug was discontinued. Transient bilirubin levels were in part attributed to increases in indirect bilirubin, which is consistent with the inhibition or organic anion-transporting protein 1B1 and 1B3 by paritaprevir and can also be attributed to ribavirin use. 24 Twenty-three percent of patients in Part II modified ribavirin dosage, with the most common cause for this being hemoglobin decrease, with no effect on overall SVR rates.
AGATE-II, a companion study to AGATE-I, examined the effect of ombitasvir/paritaprevir/ritonavir plus ribavirin in patients with HCV genotype 4 infection with cirrhosis in Egypt. 25 
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